Aclaris Therapeutics, Inc. 8-K

What Happened

• Aclaris Therapeutics, Inc. announced that on March 10, 2026 it sold 5.7 million shares of its common stock for aggregate gross proceeds of $20.0 million. The sale was made under the company’s amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co., dated February 27, 2025. The Agents reported that the shares were purchased by Frazier Life Sciences, Kalehua Capital and Adage Capital Partners LP. The disclosure was made under Regulation FD in an Item 7.01 Form 8-K filing.

Key Details

• Shares sold: 5.7 million common shares
• Gross proceeds: $20.0 million
• Sale date: March 10, 2026
• Agents/sales agreement: Leerink Partners LLC and Cantor Fitzgerald & Co.; amended and restated sales agreement dated Feb 27, 2025
• Reported purchasers: Frazier Life Sciences, Kalehua Capital, Adage Capital Partners LP

Why It Matters

• The transaction provides Aclaris with $20.0 million in gross cash proceeds, which can be used for operations, R&D, or other corporate needs.
• Issuing 5.7 million new shares increases shares outstanding and can dilute existing shareholders’ ownership and earnings per share.
• The filing is a Regulation FD disclosure (Item 7.01), signaling the company publicly reported the sale details to ensure fair disclosure to the market.